Disease-Matched
Bone Marrow Niche Models
Enabling advanced therapies for hematopoietic malignancies
by
bridging the gap between the lab and clinic
Reduce your R&D costs by 10-26%*
Evaluate drug/therapy induced hematopoietic toxicity
Test drugs/combinatory therapies for bone marrow malignancies and disorders
Develop cell and gene therapies and test their potency
Perform pre/co-clinical trials in the lab
Predict patient responses early
De-risk clinical success
Off-the-shelf*
Customizable (your selected platform meets our technology)*
Healthy / Disease-specific* or Patient / cohort-matched*
Enables more clinically relevant predictions of toxicity and efficacy prior to or in parallel with clinical testing.
Human & patient-relevant
Fit-for-purpose
Lab-ready
"Blood cancer evolves in the bone marrow; your drug candidate validation should too"
2. Our niche models are specifically designed to test treatment modalities for hemato-oncological disorders and compatible with:
1. Humaniche offers first-in-class human/patient bone marrow niches and platforms preserving the drug-response-altering complexity of diseased bone marrow niches that
Chemotherapy modalities and advanced, targeted, and cell therapies, and combination regimens
Repetitive tests and longitudinal analysis that also allows relapse/remission assessment
Bone Marrow Proxies
3. Our products integrate disease-specific marrow components within physiologically relevant, lab-compatible, and plug-&-play architectures that each is available in 3 product configurations:
of blood cancer drug candidates fail during clinical development.
of failures are linked to lack of efficacy or unexpected toxicity.
Current preclinical models often fail to accurately predict patient response to treatment.
Why act now?
Contact us to accelerate your drug development success
Are you interested in integrating Humaniche’s model technologies into your existing preclinical models and workflows to strengthen translational validation and clinical relevance?
Contact our team to discuss partnership opportunities. We respond within 1-2 business days.
Ready to screen your compounds with Humaniche's off-the-shelf disease/patient-relevant bone marrow niche models before clinical entry?
Contact us for licensing options
